KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Bristol Myers Squibb (BMY) Receivables - Other (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Receivables - Other for 17 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Other rose 4.96% to $1.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 billion, a 4.96% increase, with the full-year FY2025 number at $1.8 billion, up 372.99% from a year prior.
  • Receivables - Other was $1.8 billion for Q4 2025 at Bristol Myers Squibb, up from $1.8 billion in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $2.0 billion in Q4 2023 to a low of $248.0 million in Q2 2025.
  • A 5-year average of $1.4 billion and a median of $1.6 billion in 2021 define the central range for Receivables - Other.
  • Biggest YoY gain for Receivables - Other was 325.98% in 2025; the steepest drop was 85.21% in 2025.
  • Bristol Myers Squibb's Receivables - Other stood at $1.4 billion in 2021, then grew by 24.82% to $1.7 billion in 2022, then increased by 17.52% to $2.0 billion in 2023, then fell by 14.91% to $1.7 billion in 2024, then rose by 4.96% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Receivables - Other are $1.8 billion (Q4 2025), $1.8 billion (Q3 2025), and $248.0 million (Q2 2025).